## Gene Summary
CACNG3, or calcium voltage-gated channel auxiliary subunit gamma 3, is a member of the gamma subunit family within the voltage-dependent calcium channel complex. This gene is primarily involved in the modulation of AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor trafficking and gating, playing a crucial role in the regulation of synaptic strength and plasticity. CACNG3 is expressed in various tissues, but it has a significant presence in the brain, influencing neurological processes.

## Gene Drugs, Diseases, Phenotypes, and Pathways
CACNG3 has been associated with neuropsychiatric disorders, though specific diseases linked explicitly to this gene are less documented. The gene’s role in the modulation of synaptic transmission suggests its potential involvement in conditions characterized by synaptic dysfunctions, such as epilepsy, intellectual disability, and potentially schizophrenia. The pathways involving CACNG3 predominantly include its interactions with AMPA receptors, crucial for synaptic transmission and plasticity, impacting learning and memory processes.

## Pharmacogenetics
The pharmacogenetic implications of CACNG3 are not as extensively studied as more prominent genes in pharmacotherapy. However, understanding its role in AMPA receptor modulation can hint at potential interactions with drugs affecting glutamatergic signaling, such as those used in the treatment of neurological disorders. Drugs that influence synaptic plasticity, or those targeting epileptic seizures, might also be affected by variations in the CACNG3 gene. Further studies are required to clarify specific drug-gene interactions and their clinical significance.